Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

NCT00320879 is registered in ClinicalTrials.gov with Steno Diabetes Center Copenhagen as lead sponsor.

NCT NCT00320879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00320879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
Lead sponsor
Steno Diabetes Center Copenhagen
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2003
Completion date
November 30, 2004
Enrollment
52
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microalbuminuria, type 2 diabetes